In the liver, LCN2 modulates HDL flux through the Nedd4-1-SR-BI axis, with experimental models showing that hepatocyte-derived LCN2 can reduce atherosclerosis, underscoring its direct influence on HDL metabolism and dyslipidemia [48,49]. Here, LCN2 is linked to metabolic syndrome.